Description: Founded in 1998, TYRX develops treatments that lower the risk of surgical-site infections. One of its chief treatments is the AI GISR x Antibacterial Envelope, which is a mesh pouch implanted during surgery to hold cardiac devices such as pacemakers and defibrillators, and fend off certain pathogens. To date, more than 45,000 envelopes have been implanted in patients the U.S.
Early Successes: Bringing AI GISR x to market despite a difficult regulatory environment for new medical devices; speaking with federal officials about the importance of addressing costly infections stemming from the implantation of cardiac devices.
Key Qualities in Employees: TYRX looks for employees who are passionate, thrive in a team environment and are proficient at solving problems.
New Products: In August, TYRX launched a second-generation version of AI GISR x, which provides all the advantages of the original product with the added benefit of being able to dissolve in the body.